20/20 Biolabs, Inc. Common Stock (NASDAQ:AIDX) — Stock Price
20/20 Biolabs, Inc. Common Stock (NASDAQ:AIDX) is currently trading at $0.46 USD, down 0.59% today. Over the past 52 weeks, shares have ranged between $0.40 and $14.78. This page tracks 20/20 Biolabs, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see AIDX company net worth.
20/20 Biolabs, Inc. Common Stock (AIDX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks 20/20 Biolabs, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
20/20 Biolabs, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
20/20 Biolabs, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $1.75 Million | $1.42 Million | $11.06 Million | $9.62 Million | $2.33 Million |
| Cost of Revenue | $1.39 Million | $1.32 Million | $5.94 Million | $4.93 Million | $1.45 Million |
| Gross Profit | $360.31K | $109.14K | $5.12 Million | $4.69 Million | $877.17K |
| Research & Development | $1.26 Million | $1.41 Million | $120.04K | $193.37K | $338.87K |
| SG&A | $4.76 Million | $5.06 Million | — | — | — |
| Total Operating Expenses | $6.02 Million | $6.47 Million | $3.44 Million | $2.75 Million | $2.91 Million |
| Operating Income | $-5.66 Million | $-6.36 Million | $1.68 Million | $1.94 Million | $-2.03 Million |
| EBITDA | $-5.53 Million | $-6.19 Million | $1.97 Million | $2.07 Million | $-1.97 Million |
| EBIT | $-5.66 Million | $-6.36 Million | $1.68 Million | $1.94 Million | $-2.03 Million |
| Interest Expense | $12.65K | $27.91K | $15.69K | $12.93K | — |
| Income Before Tax | $-5.55 Million | $-6.39 Million | $2.19 Million | $2.07 Million | $-2.02 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | $-5.55 Million | $-6.39 Million | $2.19 Million | $2.07 Million | $-2.02 Million |
20/20 Biolabs, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes 20/20 Biolabs, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $3.61 Million | $6.37 Million | $12.22 Million | $10.27 Million | $4.68 Million |
| Total Current Assets | $2.03 Million | $4.30 Million | $9.73 Million | $7.94 Million | $3.83 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $135.27K | $68.83K | $764.92K | $4.22 Million | $205.07K |
| Inventory | $47.16K | $60.67K | $87.07K | $246.66K | $103.44K |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $2.08 Million | $2.08 Million | $2.84 Million | $3.38 Million | $1.29 Million |
| Total Current Liabilities | $1.36 Million | $1.01 Million | $1.63 Million | $2.25 Million | $1.25 Million |
| Long-term Debt | — | $229.16K | — | — | — |
| Net Debt | $-270.61K | $-2.02 Million | $-6.39 Million | $-1.00 Million | $-3.32 Million |
| Total Stockholder Equity | $1.53 Million | $4.29 Million | $9.37 Million | $6.89 Million | $3.39 Million |
| Retained Earnings | $-29.51 Million | $-23.96 Million | $-17.57 Million | $-19.75 Million | $-21.82 Million |
20/20 Biolabs, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how 20/20 Biolabs, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-2.60 Million | $-4.63 Million | $5.80 Million | $-1.07 Million | $-2.04 Million |
| Capital Expenditures | $5.00 | $9.38K | $261.79K | $228.15K | $184.07K |
| Free Cash Flow | $-2.60 Million | $-4.64 Million | $5.54 Million | $-1.30 Million | $-2.22 Million |
| Investing Cash Flow | — | $-43.76K | $-462.55K | $-228.15K | $1.46 Million |
| Financing Cash Flow | $293.33K | $-45.99K | $112.60K | $1.19 Million | $3.41 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $2.18 Million | $1.30 Million | — | — | — |
| Depreciation | $135.76K | $167.29K | $288.69K | $123.66K | $65.13K |
| Change in Cash | $-2.31 Million | $-4.72 Million | $5.45 Million | $-113.72K | $2.83 Million |
20/20 Biolabs, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track 20/20 Biolabs, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for 20/20 Biolabs, Inc. Common Stock.